CPT® Code 86413

The CPT® Code 86413 refers to a quantitative test for antibodies against the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), which is responsible for the disease known as COVID-19. This test is crucial for understanding the immune response to the virus, as it measures the level of antibodies produced either through natural infection or vaccination. Antibodies play a significant role in providing protection against COVID-19, but their levels can vary widely among individuals and may diminish over time. The quantitative nature of this test allows healthcare providers to assess not only the presence of antibodies but also their concentration, which can indicate the degree of protection an individual may have against the virus. The test employs a solid phase immunoassay methodology, specifically designed to detect antibodies that bind to the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein. This process involves immobilizing the RBD on a solid support, which serves as the antigen in the assay. A blood sample is collected from the patient, and the serum is then mixed with the immobilized RBD. Following incubation, anti-human antibodies are introduced to bind to any human anti-RBD antibodies present in the sample. After washing away any nonreactive substances, the concentration of the anti-RBD antibodies is determined using a standard calibration curve, and the results are reported in quantitative units. This information is not only vital for individual patient care but also contributes to broader research efforts aimed at understanding vaccine efficacy, the duration of immunity, and the need for booster vaccinations.